Saturday, September 28, 2024
Today's Paper

CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line

Landmark CARTITUDE-4 study results show CARVYKTI^® reduced the risk of death by 45 percent after three-year follow-up

Register to read this story and more for free.

Signing up for an account helps us improve your browsing experience.

Continue

See our subscription options.

Already have an account? Log in here